Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Discloses 3.66% Stake In Newly Public Company Global Blood Therapeutics Inc. (GBT)

On August 17, Global Blood Therapeutics has completed its initial public offering of 6.9 million shares, which included the exercise in full of options to purchase 900,000 additional shares. It is estimated that Global Blood raised $126.1 million from the offering, after deducting underwriting discounts and commissions and other related offering expenses. Consequently, the company plans to use the net proceeds to develop its novel therapeutics to treat grievous, non-malignant blood-based conditions, known as the sickle cell disease (SCD). The disease primarily affects African Americans in the United States; about 1 in 400 African Americans suffer from the SCD, so the market potential appears quite promising for Global Blood.

The biopharmaceutical company’s lead drug candidate is GBT440, which is a once-daily oral prophylactic therapy for patients with sickle cell disease. Even though the drug candidate is still in a Phase I/II study, Global Blood is optimistic that the drug will provide a long-term therapy that would stop the progression of the disease. However, there is tough competition for GBT440 out there in the market. Bluebird Bio Inc. (NASDAQ:BLUE) is currently developing a gene-therapy treatment for SCD as well, so it remains to be seen which company will succeed in bringing their drug candidates to the market. However, the sickle cell disease is not the only focus of Global Blood. The company also plans to develop GBT440 or one of its analogs as a potential therapy for acute and chronic hypoxemic lung disorders, which in turn broadens the market previously targeted. In the meantime, it is not surprising that Global Blood suffers losses from its operations; the company reported a net loss of $20.8 million for 2014, compared to a loss of $18.1 million in the prior year.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.